Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.

Burrack AL, Spartz EJ, Raynor JF, Wang I, Olson M, Stromnes IM.

Cell Rep. 2019 Aug 20;28(8):2140-2155.e6. doi: 10.1016/j.celrep.2019.07.059.

2.

Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.

Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD.

Cancer Immunol Res. 2019 Sep;7(9):1412-1425. doi: 10.1158/2326-6066.CIR-19-0258. Epub 2019 Jul 23.

PMID:
31337659
3.

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Burrack AL, Hulbert A, Bonson P, Black C, Brockenbrough JS, Raynor JF, Spartz EJ, Pierce RH, Greenberg PD, Hingorani SR.

Cancer Immunol Res. 2019 Jun;7(6):977-989. doi: 10.1158/2326-6066.CIR-18-0448. Epub 2019 Apr 26.

PMID:
31028033
4.

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR.

Cancer Immunol Res. 2017 Nov;5(11):978-991. doi: 10.1158/2326-6066.CIR-16-0322. Epub 2017 Oct 24.

5.

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Anderson KG, Stromnes IM, Greenberg PD.

Cancer Cell. 2017 Mar 13;31(3):311-325. doi: 10.1016/j.ccell.2017.02.008. Review.

6.

Pancreatic Cancer: Planning Ahead for Metastatic Spread.

Stromnes IM, Greenberg PD.

Cancer Cell. 2016 Jun 13;29(6):774-776. doi: 10.1016/j.ccell.2016.05.013.

7.

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen H, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR.

Cancer Cell. 2015 Nov 9;28(5):638-652. doi: 10.1016/j.ccell.2015.09.022. Epub 2015 Oct 29.

8.

New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Schmitt TM, Stromnes IM, Chapuis AG, Greenberg PD.

Clin Cancer Res. 2015 Dec 1;21(23):5191-7. doi: 10.1158/1078-0432.CCR-15-0860. Epub 2015 Oct 13. Review.

9.

Molecular pathways: myeloid complicity in cancer.

Stromnes IM, Greenberg PD, Hingorani SR.

Clin Cancer Res. 2014 Oct 15;20(20):5157-70. doi: 10.1158/1078-0432.CCR-13-0866. Epub 2014 Jul 21. Review.

10.

Stromal reengineering to treat pancreas cancer.

Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR.

Carcinogenesis. 2014 Jul;35(7):1451-60. doi: 10.1093/carcin/bgu115. Epub 2014 Jun 7. Review.

11.

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR.

Gut. 2014 Nov;63(11):1769-81. doi: 10.1136/gutjnl-2013-306271. Epub 2014 Feb 20.

12.

B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system.

Pierson ER, Stromnes IM, Goverman JM.

J Immunol. 2014 Feb 1;192(3):929-39. doi: 10.4049/jimmunol.1302171. Epub 2013 Dec 23.

13.

Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD.

Immunol Rev. 2014 Jan;257(1):145-64. doi: 10.1111/imr.12141. Review.

14.

Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.

Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD.

Blood. 2013 Jul 18;122(3):348-56. doi: 10.1182/blood-2013-01-478164. Epub 2013 May 14.

15.

Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.

Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, Tan X, Kim TD, Choi I, Blattman JN, Greenberg PD.

J Immunol. 2012 Aug 15;189(4):1812-25. doi: 10.4049/jimmunol.1200552. Epub 2012 Jul 13.

16.

Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections.

Johnson PL, Kochin BF, McAfee MS, Stromnes IM, Regoes RR, Ahmed R, Blattman JN, Antia R.

J Virol. 2011 Jun;85(11):5565-70. doi: 10.1128/JVI.00166-11. Epub 2011 Mar 16.

17.

Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD.

J Clin Invest. 2010 Oct;120(10):3722-34. doi: 10.1172/JCI41991. Epub 2010 Sep 20.

18.

Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM.

Nat Med. 2008 Mar;14(3):337-42. doi: 10.1038/nm1715. Epub 2008 Feb 17.

19.

Passive induction of experimental allergic encephalomyelitis.

Stromnes IM, Goverman JM.

Nat Protoc. 2006;1(4):1952-60.

PMID:
17487182
20.

Active induction of experimental allergic encephalomyelitis.

Stromnes IM, Goverman JM.

Nat Protoc. 2006;1(4):1810-9.

PMID:
17487163
21.

Osteopontin-induced survival of T cells.

Stromnes IM, Goverman JM.

Nat Immunol. 2007 Jan;8(1):19-20. No abstract available.

PMID:
17179966
22.

Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection.

Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, Ohlen C, Greenberg PD, Stromnes IM, Iwashiro M, Sakaguchi S, Evans LH, Peterson KE, Yang G, Hasenkrug KJ.

Immunity. 2004 Mar;20(3):293-303. Erratum in: Immunity. 2004 May;20(5):653.

23.

Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice.

Stromnes IM, Dittmer U, Schumacher TN, Schepers K, Messer RJ, Evans LH, Peterson KE, Race B, Hasenkrug KJ.

J Virol. 2002 Mar;76(5):2225-32.

24.

Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression.

Dittmer U, Race B, Peterson KE, Stromnes IM, Messer RJ, Hasenkrug KJ.

J Virol. 2002 Jan;76(1):450-4.

25.

Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection.

Iwashiro M, Messer RJ, Peterson KE, Stromnes IM, Sugie T, Hasenkrug KJ.

Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9226-30. Epub 2001 Jul 17.

26.

Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Dittmer U, Peterson KE, Messer R, Stromnes IM, Race B, Hasenkrug KJ.

J Virol. 2001 Jan;75(2):654-60.

27.

CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection.

Iwashiro M, Peterson K, Messer RJ, Stromnes IM, Hasenkrug KJ.

J Virol. 2001 Jan;75(1):52-60.

Supplemental Content

Loading ...
Support Center